Mentari Therapeutics completes InMed merger and $490M private placements; begins Nasdaq trading as MTRI

On November 9, 2026, Mentari Therapeutics closed its merger with InMed Pharmaceuticals and began trading on the Nasdaq Capital Market under the ticker MTRI. Just before closing, it completed private placements worth about $490 million in gross proceeds, which it says funds operations into 2029. The company is developing PACAP-targeting migraine-prevention antibodies: MT-001 is in Phase 1 with initial data expected mid-2027, and a regulatory filing for the bispecific MT-002 is planned for Q1 2027.

09 Nov 2026 · InMed Pharmaceuticals Inc. INM · Company news

Company's press release (SEC filing): InMed Pharmaceuticals Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →

Financing

Mentari Therapeutics completes InMed merger and $490M private placements; begins Nasdaq trading as MTRI

IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M

Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597

Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants

Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities

Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds

Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq